Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Oropharyngeal cancer
Results 1-25 of 187 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1216, NCI-2013-00500, NCT01810913
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients with Stage III-IV Oropharyngeal Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0825, NCI-2013-01879, NCT01893307
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
Acupuncture in Treating Dry Mouth Caused by Radiation Therapy in Patients with Head and Neck Cancer
Phase: Phase III
Type: Supportive care
Age: Not specified
Trial IDs: 97115, NCI-2011-02073, CDR0000674208, WF 97115, WFU-97115, MDA-04-01, NCT01141231
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Radiation Therapy with or without Cisplatin in Treating Patients with Oropharyngeal Cancer Previously Treated with Surgery
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: 201207059, NCI-2012-01230, NCT01687413
Doxepin Hydrochloride or DLA Rinse in Reducing Oral Mucositis Pain in Patients with Head and Neck Cancer undergoing Radiation Therapy
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: A221304, NCI-2014-01877, NCT02229539
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-040, NCI-2014-02662, 2014-001749-26, NCT02252042
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients with Head and Neck Cancer Undergoing Radiation Therapy
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: ENT0042, NCI-2015-00176, 351, NCT02369835
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D4193C00002, NCI-2015-01842, NCT02369874
Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D419LC00001, NCI-2015-02221, NCT02551159
Intensity-Modulated Radiation Therapy, Pemetrexed Disodium, and Erlotinib Hydrochloride in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 60107, NCI-2009-01250, CCCWFU-IRB00003457, CDR0000578838, LILLY-CCCWFU-60107, NCT01580449, P30CA012197, NCT00573989
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 603EUSA03, NCI-2010-01741, NCT00901732
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients with Cancer Receiving Anti-Angiogenesis Therapy
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VARIMG0002, NCI-2013-00535, NCT01806675
Buparlisib and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1972, NCI-2013-00586, BKM120, IRB12-1972-CR002, NCT01816984
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2104, NCI-2014-02359, 2014-000579-20, NCT02205398
T-cell Receptor Gene Therapy Targeting HPV-16 E6 in Treating Patients with Metastatic, Recurrent, or Refractory HPV-Related Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0005, NCI-2014-02319, 1407-1331, 337514, P141607, RD-14-VII-09, RD-14-VIII-09, NCT02280811
A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204, NCI-2015-00040, NCT02327078
Start Over